Calliditas reveals pivotal setanaxib data
Results are from company’s phase 2 head and neck cancer trial with lead NOX inhibitor candidate
Read More
Tag: setanaxib
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
